-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target

Benzinga·12/09/2025 13:03:54
語音播報
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.